$OM

Outset Medical, Inc.

0
1
0
$47K
Brottem John L.
0%
See all $OM insider activity →
Low

Outset Medical, Inc. (OM): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Outset Medical, Inc. (OM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, John Brottem informed Outset Medical, Inc. (the “Company”) of his decision to depart from the Company a

Outset Medical (OM) Q2 2026 Earnings Call Transcript

Outset Medical (OM) reported Q2 2026 revenue of $31.6 million, up 1% year over year and 14% sequentially. Console revenue was $9.5 million, up 6% YoY, while product revenue fell 5% to $21.9 million. Non-GAAP gross margin was 42.2%. Cash and investments were $151 million. Full-year revenue guidance is $125 million to $130 million.

Outset Medical, Inc. (OM): Results of Operations and Financial Condition

Outset Medical, Inc. (OM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Outset Medical Reports Second Quarter 2026 Results San Jose, CA – August 6, 2026 – Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today

OM sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning OM (Outset Medical, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent OM coverage spans earnings, corporate actions and financial news.

In the last 30 days, OM insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($47K). The most active reporter was Brottem John L., General Counsel, with 1 filing.

What's driving OM

  • Departure of a senior legal officer may cause short‑term uncertainty but no immediate financial impact.

    SEC EDGAR 8-K · Aug 28, 2026

  • The earnings call provides fresh operating datapoints (revenue, margins, cash use) and a new contracted backlog catalyst via HCA, supporting near-term sentiment and model updates.

    fool.com · Aug 14, 2026

  • The quarter showed margin expansion and cash burn, while the HCA three-year $40M refresh deal supports backlog visibility and potential adoption.

    SEC EDGAR 8-K · Aug 6, 2026

  • This is a disclosed ownership update by a major asset manager, but it does not provide a new operational catalyst for Outset Medical.

    stocktitan.net · Jul 29, 2026

  • Target increase implies improved expected value under the revised copper price deck.

    theglobeandmail.com · Jul 14, 2026

alphai scores every news story that mentions OM with an AI model for sentiment and relevance, and aggregates insider trades from Outset Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $OM

Score
$OMLow

Outset Medical, Inc. (OM): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Outset Medical, Inc. (OM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, John Brottem informed Outset Medical, Inc. (the “Company”) of his decision to depart from the Company a

$OMMedAI 8/10

Outset Medical (OM) Q2 2026 Earnings Call Transcript

Outset Medical (OM) reported Q2 2026 revenue of $31.6 million, up 1% year over year and 14% sequentially. Console revenue was $9.5 million, up 6% YoY, while product revenue fell 5% to $21.9 million. Non-GAAP gross margin was 42.2%. Cash and investments were $151 million. Full-year revenue guidance is $125 million to $130 million.

$OMMed

Outset Medical, Inc. (OM): Results of Operations and Financial Condition

Outset Medical, Inc. (OM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Outset Medical Reports Second Quarter 2026 Results San Jose, CA – August 6, 2026 – Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today

Tuesday’s analyst upgrades and downgrades

National Bank Financial analysts revised precious-metals and copper forecasts ahead of Q2 earnings, citing realized gold at $4,508/oz and silver at $73/oz, and copper at $5.82/lb. They cut 2026 gold and silver assumptions and adjusted target prices for multiple miners, generally lower. TD Cowen upgraded First Quantum Minerals on a likely Cobre Panama restart by year-end.

$OMMed

Outset Medical, Inc. (OM): Results of Operations and Financial Condition

Outset Medical, Inc. (OM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 2 om-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THA

$OMMedAI 8/10

Osisko logs 3. 49 % copper at Gaspé project in Quebec

Osisko Metals (TSX: OM) began its 2026 drilling at the Gaspé copper project in Quebec, aiming to add mineralization within the planned Whittle pit. It reported hole 30-1196: 80m at 1.93% Cu from 196m, including 30m at 3.49% Cu from 224m. Scotia Capital said intercepts fall in modelled waste rock, potentially supporting resource conversion.

Related tickers